MX2019010600A - Usos médicos para tratar hepatitis c. - Google Patents

Usos médicos para tratar hepatitis c.

Info

Publication number
MX2019010600A
MX2019010600A MX2019010600A MX2019010600A MX2019010600A MX 2019010600 A MX2019010600 A MX 2019010600A MX 2019010600 A MX2019010600 A MX 2019010600A MX 2019010600 A MX2019010600 A MX 2019010600A MX 2019010600 A MX2019010600 A MX 2019010600A
Authority
MX
Mexico
Prior art keywords
methods
treating hepatitis
inhibitors
hepatitis
hcv
Prior art date
Application number
MX2019010600A
Other languages
English (en)
Inventor
M Kati Warren
A Matulenko Mark
G Keddy Ryan
K Pratt John
J Maring Clarence
Wagner Rolf
Krishnan Preethi
Teresa, (Lok-Chan) Ng
J Pilot-Matias Tami
C Mistry Neeta
J Reisch Thomas
Dachun Liu
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49304326&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019010600(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MX2019010600A publication Critical patent/MX2019010600A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se describen inhibidores de VHC pan-genotípicos. Esta invención también se relaciona a métodos para utilizar estos inhibidores par utilizar estos inhibidores para tratar infección por VHC.
MX2019010600A 2012-09-18 2015-03-18 Usos médicos para tratar hepatitis c. MX2019010600A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261702564P 2012-09-18 2012-09-18

Publications (1)

Publication Number Publication Date
MX2019010600A true MX2019010600A (es) 2020-02-03

Family

ID=49304326

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015003501A MX367796B (es) 2012-09-18 2013-09-17 Usos médicos para tratar hepatitis c.
MX2019010600A MX2019010600A (es) 2012-09-18 2015-03-18 Usos médicos para tratar hepatitis c.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015003501A MX367796B (es) 2012-09-18 2013-09-17 Usos médicos para tratar hepatitis c.

Country Status (25)

Country Link
US (1) US20140080868A1 (es)
EP (2) EP2897611B1 (es)
JP (4) JP6297044B2 (es)
CN (1) CN104797253A (es)
AU (2) AU2013318302B2 (es)
BR (1) BR112015006037B1 (es)
CA (1) CA2884539C (es)
CY (1) CY1122442T1 (es)
DK (1) DK2897611T3 (es)
ES (1) ES2755089T3 (es)
HK (1) HK1209319A1 (es)
HR (1) HRP20191939T1 (es)
HU (1) HUE046544T2 (es)
LT (1) LT2897611T (es)
MX (2) MX367796B (es)
NZ (1) NZ630581A (es)
PL (1) PL2897611T3 (es)
PT (1) PT2897611T (es)
RS (1) RS59640B1 (es)
RU (1) RU2665365C2 (es)
SG (2) SG11201502095SA (es)
SI (1) SI2897611T1 (es)
TW (1) TWI621436B (es)
WO (1) WO2014047039A1 (es)
ZA (1) ZA201501752B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX367796B (es) * 2012-09-18 2019-09-06 Abbvie Inc Usos médicos para tratar hepatitis c.
WO2015153792A1 (en) * 2014-04-02 2015-10-08 Abbvie Inc. Methods for treating hcv
KR102210935B1 (ko) * 2013-03-14 2021-02-02 애브비 인코포레이티드 C형 간염 치료용 2가지 항바이러스제의 병용물
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
BR112016022976A8 (pt) 2014-04-02 2021-07-20 Abbvie Inc métodos para o tratamento de hcv
US20160375017A1 (en) 2015-06-26 2016-12-29 Abbvie Inc. Solid Pharmaceutical Compositions for Treating HCV
AU2016283018C1 (en) * 2015-06-26 2022-03-03 Abbvie Inc. Solid pharmaceutical compositions for treating HCV
CA2991417A1 (en) * 2015-07-08 2017-01-12 Abbvie Inc. Methods for treating hcv
EA201890334A1 (ru) * 2015-07-17 2018-06-29 Эббви Инк. Твердые фармацевтические композиции для лечения вируса гепатита с
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
GB202113944D0 (en) * 2021-09-29 2021-11-10 Univ Liverpool Injectable formulations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200800265A (en) * 2006-02-09 2008-01-01 Schering Corp Combinations comprising HCV protease inhibitor(s) and HCV polymerase inhibitor(s), and methods of treatment related thereto
AR075584A1 (es) * 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
US8937150B2 (en) * 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US9394279B2 (en) * 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
CN104023726A (zh) * 2011-10-21 2014-09-03 艾伯维公司 用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333)
MX367796B (es) * 2012-09-18 2019-09-06 Abbvie Inc Usos médicos para tratar hepatitis c.

Also Published As

Publication number Publication date
JP2015528511A (ja) 2015-09-28
NZ630581A (en) 2017-02-24
BR112015006037B1 (pt) 2022-05-17
TWI621436B (zh) 2018-04-21
WO2014047039A1 (en) 2014-03-27
CY1122442T1 (el) 2021-01-27
JP6297044B2 (ja) 2018-03-20
ES2755089T3 (es) 2020-04-21
AU2013318302A1 (en) 2015-04-02
TW201412311A (zh) 2014-04-01
JP2019194241A (ja) 2019-11-07
RS59640B1 (sr) 2020-01-31
JP2018109035A (ja) 2018-07-12
EP2897611A1 (en) 2015-07-29
AU2013318302B2 (en) 2018-02-22
EP2897611B1 (en) 2019-07-24
ZA201501752B (en) 2016-08-31
SG11201502095SA (en) 2015-05-28
JP6556884B2 (ja) 2019-08-07
HK1209319A1 (en) 2016-04-01
RU2015114543A (ru) 2016-11-10
AU2018203608A1 (en) 2018-06-14
US20140080868A1 (en) 2014-03-20
HRP20191939T1 (hr) 2020-01-10
SI2897611T1 (sl) 2019-12-31
DK2897611T3 (da) 2019-11-04
LT2897611T (lt) 2019-12-10
MX367796B (es) 2019-09-06
AU2018203608B2 (en) 2019-12-19
HUE046544T2 (hu) 2020-03-30
EP3597190A1 (en) 2020-01-22
CA2884539A1 (en) 2014-03-27
SG10201702248UA (en) 2017-04-27
CA2884539C (en) 2022-06-21
RU2665365C2 (ru) 2018-08-29
MX2015003501A (es) 2015-10-26
PL2897611T3 (pl) 2020-03-31
BR112015006037A2 (pt) 2017-07-04
JP2021054849A (ja) 2021-04-08
CN104797253A (zh) 2015-07-22
PT2897611T (pt) 2019-11-27

Similar Documents

Publication Publication Date Title
MX2019010600A (es) Usos médicos para tratar hepatitis c.
PH12017550022A1 (en) Phosphoramidates for the treatment of hepatitis b virus
MX336580B (es) Metodos para el tratamiento de vhc.
SA516370684B1 (ar) مثبطات بوليمراز فيروس الالتهاب الكبدي سي
EA201391152A1 (ru) Ингибиторы вируса гепатита с
EA201691261A1 (ru) Новые дигидрохинолизиноны для лечения и профилактики инфекции, вызванной вирусом гепатита b
EA201390190A1 (ru) Ингибиторы вируса гепатита с
EA030115B9 (ru) Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
MX2016005393A (es) Metodos para tratar vhc.
GB201103062D0 (en) Method
EA201270616A1 (ru) Ингибиторы вируса гепатита с
PH12014502513A1 (en) Nampt inhibitors
MX2014013752A (es) Inhibidores de nampt.
SG195383A1 (en) Yeast-based compositions and methods for the treatment or prevention of hepatitis delta virus infection
EA201591705A1 (ru) Композиции и способы для диагностики и лечения рака печени
MX2015003701A (es) Composiciones para tratamiento.
PH12016502559A1 (en) Isoindoline derivatives for use in the treatment of a viral infection
AU2013318309A8 (en) Methods for treating hepatitis C
MX348311B (es) Inhibidores nampt.
HK1208364A1 (en) Method for treating hepatitis c virus infection using quercetin- containing compositions
EA201890884A1 (ru) Способ и композиции для нежелательных и аномальных мышечных сокращений
IN2014DN00254A (es)
PH12016500903A1 (en) Novel methods for treating neurodegenerative diseases
GB201114633D0 (en) Anti-viral therapy
PH12014502065A1 (en) Vesicular formulations